Merck reported positive top-line results from the pivotal Phase IIb/III Brunello trial of remigromig in adults with diabetic macular edema, reporting noninferiority versus active control on key visual acuity endpoints. The readout also included language that analysts interpreted as suggesting a possible safety downside. The discussion around Brunello follows the broader competitive race in retinal disease, where Big Pharma is increasingly betting on pathway innovation alongside existing anti-VEGF standards. Remigromig is described as a tetravalent, trispecific antibody designed to activate the Wnt pathway. At the same time, competitor Surrozen defended the implications from the latest trial commentary, signaling the market’s sensitivity to safety language even when efficacy signals are strong. Investors and clinicians typically treat DME outcomes as a blend of efficacy magnitude, durability, and ocular risk profile.